SEC Form 4 · accession 0001643074-16-000003
Axovant Sciences Ltd. · AXON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Altmeyer
Officer — Pres&Chief Commercial Officer
Period of report
Mar 10, 2016
Accepted (ET)
Mar 14, 2016 · 10:11 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636050
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Mar 10, 2016 | P | 2,300 | $11.14 | A | 2,300 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported represents the weighted average price of shares acquired in multiple transactions at prices ranging from $11.10 to $11.17 per share, inclusive. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares acquired at each separate price.